Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Inventory: 2011-2024

Historic Inventory for Ligand Pharmaceuticals (LGND) over the last 14 years, with Dec 2024 value amounting to $14.1 million.

  • Ligand Pharmaceuticals' Inventory fell 28.91% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year decrease of 28.91%. This contributed to the annual value of $14.1 million for FY2024, which is 41.12% down from last year.
  • Ligand Pharmaceuticals' Inventory amounted to $14.1 million in FY2024, which was down 41.12% from $24.0 million recorded in FY2023.
  • In the past 5 years, Ligand Pharmaceuticals' Inventory ranged from a high of $27.3 million in FY2021 and a low of $13.3 million during FY2022.
  • Over the past 3 years, Ligand Pharmaceuticals' median Inventory value was $14.1 million (recorded in 2024), while the average stood at $17.1 million.
  • In the last 5 years, Ligand Pharmaceuticals' Inventory surged by 263.03% in 2020 and then plummeted by 51.35% in 2022.
  • Ligand Pharmaceuticals' Inventory (Yearly) stood at $26.5 million in 2020, then climbed by 3.17% to $27.3 million in 2021, then slumped by 51.35% to $13.3 million in 2022, then surged by 80.30% to $24.0 million in 2023, then slumped by 41.12% to $14.1 million in 2024.